Europe’s medical devices industry saw a rise of 12.7% in overall deal activity during Q3 2019, when compared to the four-quarter average, according to GlobalData’s deals database.
A total of 80 deals worth $627.42 million were announced for the region during Q3 2019, against the last four-quarter average of 71 deals.
Of all the deal types, venture financing saw most activity in Q3 2019 with 40, representing a 50% share for the region.
In second place was M&A with 29 deals, followed by private equity deals with 11 transactions, respectively capturing a 36.3% and 13.8% share of the overall deal activity for the quarter.
In terms of value of deals, venture financing was the leading category in Europe’s medical devices industry with $539.4 million, while M&A and private equity deals totalled $80.26 million and $7.76 million, respectively.
The combined value of the top five medical devices deals stood at $395.18 million, against the overall value of $627.42 million recorded for the quarter.
The top five medical devices industry deals of Q3 2019 tracked by GlobalData were:
- Cambridge Innovation Capital, Escala Capital Investments Cyprus, LGT Impact Ventures, Silk Road Fund and Watrium’s $242.67 million venture financing of CMR Surgical
- The $47.03 million venture financing of Quanta Dialysis Technologies by btov Partners, Seroba Life Sciences and Wellington Partners
- BNP Paribas Fortis Private Equity, Capricorn Venture Partners, Earlybird Venture Capital GmbH & Co, Gimv, Life Sciences Partners, Societe Regionale d’Investissement de Wallonie and The Federal Holding and Investment’s $44.03 million venture financing of iStar Medical
- The $33.59 million acquisition of Cytena by Cellink
- CellaVision’s acquisition of RAL Diagnostics for $27.85 million.
